Molecular Partners and Orano Med collaborate to develop novel Radio-DARPin therapeutics
![Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies](https://worldbusinessoutlook.com/wp-content/uploads/2024/01/Molecular-Partners-and-Orano-Med-Announce-Co-Development-Agreement-for-Radio-DARPin-Therapies-1024x576.jpg)
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in targeted alpha therapy, have announced a collaboration to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their […]